[Conference Materials, Panel to Review GP-160 Vaccine Candidate (1992: Bethesda, Maryland)]

Fiscal Year 1993
Department of Defense Appropriations Act
(P.L. 102-396)
Excerpt from the Bill
Provided further, That $20,000,000 of the funds appropriated in this
paragraph may be made available in the Acquired Immune Deficiency
Syndrome program element only for a large-scale Phase III clinical
investigation of the GP-160 vaccine: Provided further, That the funds
referred to in the preceding proviso may be obligated unless, within six
months after the date of the enactment of this Act, the Secretary of
Defense, the Director of the National Institutes of Health, and the
Commissioner of Food and Drugs submit to the Committees on
Appropriations of the Senate and House of Representatives a written
certification containing a determination of such officials that the largescale Phase III clinical investigation should not proceed, the reasons for
that determination, and an assessment of the GP-160 vaccine:
Provided further, That if such certification is presented, the Secretary
of Defense may use these funds only for other AIDS research needs of
the Department of Defense; and the Senate agree to the same.